Taiwan Nationwide Study of First-Line ALK-TKI Therapy in ALK-Positive Lung Adenocarcinoma

Overview

Journal Target Oncol

Specialty Oncology

Date 2024 Oct 11

PMID 39392550

Authors

Zhe-Rong Zheng

Jia-Jun Wu

Chun-Ju Chiang

Tzu-I Chen

Kun-Chieh Chen

Cheng-Hsiang Chu

Sheng-Yi Lin

Sung-Liang Yu

Wen-Chung Lee

Tsang-Wu Liu

Gee-Chen Chang

Affiliations

Soon will be listed here.

Abstract

Background: The clinical outcomes of patients with anaplastic lymphoma kinase-positive (ALK+) advanced lung adenocarcinoma vary according to real-world data.

Objective: In this study, we aimed to investigate the treatment discontinuation (TTD) and overall survival (OS) of patients with ALK+ advanced lung adenocarcinoma treated with first-line ALK-TKIs in Taiwan.

Patients And Methods: This retrospective study evaluated all advanced lung adenocarcinoma patients registered in the National Taiwan Cancer Registry from 2017 to 2020 who had ALK rearrangement and received ALK-TKI treatment, using data from Taiwan's National Health Insurance Research Database (NHIRD). The TKI treatment sequences were classified into first generation (G1: crizotinib), second generation (G2: ceritinib, alectinib, brigatinib), and third generation (G3: lorlatinib).

Results: A total of 587 patients were analyzed, with a median age of 60.0 years, 91 (15.5%) aged ≥ 74 years, 293 (49.9%) female, 397 (67.6%) never smoked, and 534 (91.0%) with stage IV disease. Patients who received next-generation ALK-TKIs during the treatment course had longer median time to ALK-TKI TTD and OS. The TTD of the G1, G1+2, G1+2+3, G2, and G2+3 groups was 7.5 (5.4-11.1), 40.6 (29.4-not calculated (NC)), 50.3 (41.3-NC), 34.3 (29.2-43.0), and 36.3 (22.4-NC) months, respectively (p < 0.001). The median OS of the patients in the G1, G1+2, G1+2+3, G2, and G2+3 groups was 10.6 (7.5-14.6), not reached (NR) (NC-NC), NR (NC-NC), 43.0 (36.3-NC), and NR (30.3-NC) months, respectively (p < 0.001). Compared with treatment with crizotinib alone, the multivariate analysis revealed that treatment with next-generation TKIs was independently associated with longer TTD (G1+2 (hazard ratio (HR), 0.24; 95% CI 0.17-0.33; p < 0.001), G1+2+3 or G1+3 (HR, 0.17; 95% confidence interval (CI), 0.10-0.28; p < 0.001), G2 (HR, 0.26; 95% CI 0.19-0.36; p < 0.001), and G2+3 (HR, 0.25; 95% CI 0.14-0.44; p < 0.001)) and median OS (G12 (HR, 0.24; 95% CI 0.17-0.35; p < 0.001), G1+2+3 or G1+3 (HR, 0.09; 95% CI 0.04-0.21; p < 0.001), G2 (HR, 0.22; 95% CI 0.15-0.31; p < 0.001), and G2+3 (HR, 0.20; 95% CI 0.10-0.42; p < 0.001)).

Conclusions: For patients with ALK+ NSCLC, treatments including next-generation ALK-TKIs were independently associated with longer survival outcomes.

References

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Bronte G, Rizzo S, La Paglia L, Adamo V, Siragusa S, Ficorella C . Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev. 2010; 36 Suppl 3:S21-9. DOI: 10.1016/S0305-7372(10)70016-5. View

Hsu K, Ho C, Hsia T, Tseng J, Su K, Wu M . Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in Taiwan. PLoS One. 2015; 10(3):e0120852. PMC: 4366385. DOI: 10.1371/journal.pone.0120852. View

Chang G, Yang T, Chen K, Hsu K, Huang Y, Su K . ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients. Sci Rep. 2020; 10(1):21063. PMC: 7713243. DOI: 10.1038/s41598-020-78152-1. View

Pikor L, Ramnarine V, Lam S, Lam W . Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer. 2013; 82(2):179-89. DOI: 10.1016/j.lungcan.2013.07.025. View

Schneider J, Lin J, Shaw A . ALK-positive lung cancer: a moving target. Nat Cancer. 2023; 4(3):330-343. PMC: 10754274. DOI: 10.1038/s43018-023-00515-0. View

Cooper A, Sequist L, Lin J . Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol. 2022; 19(8):499-514. PMC: 9621058. DOI: 10.1038/s41571-022-00639-9. View

Peters S, Camidge D, Shaw A, Gadgeel S, Ahn J, Kim D . Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(9):829-838. DOI: 10.1056/NEJMoa1704795. View

10.

Camidge D, Kim H, Ahn M, Yang J, Han J, Lee J . Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 379(21):2027-2039. DOI: 10.1056/NEJMoa1810171. View

11.

Shaw A, Bauer T, de Marinis F, Felip E, Goto Y, Liu G . First-Line Lorlatinib or Crizotinib in Advanced -Positive Lung Cancer. N Engl J Med. 2020; 383(21):2018-2029. DOI: 10.1056/NEJMoa2027187. View

12.

Gibson A, Box A, Dean M, Elegbede A, Hao D, Sangha R . Retrospective Real-World Outcomes for Patients With -Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors. JTO Clin Res Rep. 2021; 2(4):100157. PMC: 8474209. DOI: 10.1016/j.jtocrr.2021.100157. View

13.

Patel A, Batra U, Prasad K, Dabkara D, Ghosh J, Sharma M . Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: A multicenter study from India. Curr Probl Cancer. 2020; 44(3):100571. DOI: 10.1016/j.currproblcancer.2020.100571. View

14.

Tsimafeyeu I, Moiseenko F, Orlov S, Filippova E, Belonogov A, Nebesnykh A . Overall Survival of Patients With -Positive Metastatic Non-Small-Cell Lung Cancer in the Russian Federation: Nationwide Cohort Study. J Glob Oncol. 2019; 5:1-7. PMC: 6550093. DOI: 10.1200/JGO.19.00024. View

15.

Condoluci A, Mazzara C, Zoccoli A, Pezzuto A, Tonini G . Impact of smoking on lung cancer treatment effectiveness: a review. Future Oncol. 2016; 12(18):2149-61. DOI: 10.2217/fon-2015-0055. View

16.

Zheng Z, Ku H, Chen K, Chiang C, Wang C, Chen C . Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naïve ALK-positive advanced lung adenocarcinoma. Front Oncol. 2023; 13:1063695. PMC: 10064125. DOI: 10.3389/fonc.2023.1063695. View

17.

Solomon B, Besse B, Bauer T, Felip E, Soo R, Camidge D . Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018; 19(12):1654-1667. DOI: 10.1016/S1470-2045(18)30649-1. View

18.

Solomon B, Mok T, Kim D, Wu Y, Nakagawa K, Mekhail T . First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014; 371(23):2167-77. DOI: 10.1056/NEJMoa1408440. View

19.

Soria J, Tan D, Chiari R, Wu Y, Paz-Ares L, Wolf J . First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017; 389(10072):917-929. DOI: 10.1016/S0140-6736(17)30123-X. View

20.

Tseng C, Chiang C, Tseng J, Yang T, Hsu K, Chen K . EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. Oncotarget. 2017; 8(58):98384-98393. PMC: 5716737. DOI: 10.18632/oncotarget.21842. View